News About: Pharm. Affairs
The OTC appetite suppressant market is rising with a 32.9 rapid increase last year
It is known that the OTC appetite suppressant market has been rapidly growing.
According to the Ministry of Food and Drug Safety on the 21st, the ‘alginic acid-carboxymethylcellulose sodium’ complex market, occupied ...
Insurance drug prices of 12 products, such as Avastin and Pegasys, will be voluntarily decreased
Insurance fees of 12 insurance pharmaceutical products, such as the Roche Korea’s antibody, Avastin, will be voluntarily reduced by requests of pharmaceutical manufacturers due to the extension of the benefit standard...
The first domestic insurance benefit for an oral hepatitis C treatment with the ‘shocking’ drug price
An oral hepatitis C treatment will acquire the health insurance benefit for the first time in Korea. The subject of the news is the BMS’s dual therapy of ‘Daklinza(generic name: daclatasvir)’ and ‘Sunvepra(asunaprevir...
Forxiga will be accepted to be used for the dual therapy with insulin while Suglat is going to be newly registeredThe insurance benefit standard of diabetes drugs has been expanded. Followed by DPP-4 inhibitors, the dual therapy of a SGLT-2 inhibitor, ‘Forxiga(dapagliflozin),’ is also expec...
|
Celebrex has faced significant prescription reduction while its generics are not popular in the market, either
Celebrex, the Pfizer’s COX-2 type anti-inflammatory drug, has encountered significant decreases in prescriptions due to entry of its generics. Celebrex, whose patent was expired on the 11th last June, has faced generi...
The new drugs domestically approved in the first quarter
New drugs approved in this first quarter appear to be outstanding.
According to the present condition of pharmaceutical approvals from the Ministry of Health and Welfare, starting with the Novartis Korea’s Zykadia(ge...
Over the pressure of the pharmaceutical industry to delay the Drug Price Reduction, the Ministry of Health and Welfare stated “as it is scheduled”
Over the argument of the pharmaceutical industry to defer the Drug Price Reduction followed by the Real Transaction Price Investigation, the Ministry of Health and Welfare has expressed negative opinions.
On the 14th...
Actavis, a foreign generic company, will enter the domestic market, followed after Teva and AlvogenAnother generic of a multinational brand is expected to enter the domestic market.
The company is the top U.S. generic company, Actavis. After taking over the pharmaceutical co...
|
Daklinza troubled with the September launch of Sovaldi
It seems that a domestic approval of the hepatitis type C treatment, ‘Sovaldi(generic name: sofosbuvir),’ will be made between September and October. As the approval of Sovaldi has come closer, BMS Korea has also been...
The countdown to the domestic entry of an insulin decreasing the risk of hypoglycemia, pre-noticing a war of nerves
As the countdown has begun to the domestic launch of the next-generation basal insulin diabetes treatment having low risk of hypoglycemia, the markets concerned has shown high interests.
Recently, the Novo Nordisk’s ...
